1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ISR IMMUNE SYSTEM REGULATION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 9,080 | +0,75 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress | Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO study in the second half of 2025 and submit a Biologics... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,262 | +0,53 % | Pacific Biosciences Of California, Inc. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for Pacific Biosciences of California, Inc. (PACB):Earnings: $3.57 million in Q4 vs. -$82.02 million in the same period last year.
EPS:... ► Artikel lesen | |
| CENTOGENE | 0,150 | +25,00 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,450 | +1,65 % | ICE - ATAI Life Sciences - Das war einfach! - Vorher, nachher | ||
| BIOMERIEUX | 115,60 | +2,30 % | QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology | PARIS (dpa-AFX) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements... ► Artikel lesen | |
| CYCLACEL | 0,310 | -8,82 % | Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership | ||
| SYROS PHARMACEUTICALS | 0,071 | -9,62 % | Syros Pharmaceuticals, Inc. Announces Voluntary Delisting from Nasdaq and SEC Deregistration | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed... ► Artikel lesen | |
| GENUS | 21,600 | +0,93 % | Genus HY Pre-Tax Profit Down; Declares Unchanged Interim Dividend Of 10.3p/shr | LONDON (dpa-AFX) - Genus plc (GNS.L) reported that its profit before tax for the six months ended 31 December 2024 dropped to 3.3 million pounds from last year's 14.3 million pounds. The latest... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,420 | 0,00 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 14,000 | -11,95 % | AnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and... ► Artikel lesen | |
| ABIONYX PHARMA | 1,390 | +9,62 % | ABIONYX Pharma: World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances | Commitment to the LCAT patient community for the creation of a patient association and assistance with early diagnosis Preparation for the submission of the Marketing Authorization Application... ► Artikel lesen | |
| MEIRAGTX | 6,950 | +12,10 % | MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy | As disclosed in the paper, 4 out of 4 young children with the AIPL1-related retinal dystrophy, LCA4, benefited substantially from unilateral subretinal administration of rAAV8.hRKp.AIPL1 with improved... ► Artikel lesen | |
| METABOLIC EXPLORER | 0,095 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 8,850 | +2,91 % | Akeso, Inc.: Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy | HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,131 | -2,24 % | Isofol Medical AB: Isofol Medical AB (publ) publishes year-end report, January - December 2024 | GOTHENBURG, Sweden, February 19, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January - December 2024 is now available on the company's... ► Artikel lesen |
ISR IMMUNE SYSTEM REGULATION HOLDING AB gehört der Branche Biotechnologie an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISR IMMUNE SYSTEM REGULATION HOLDING AB finden Sie auf Wallstreet Online.
